Related Experiment Video

Updated: Jun 7, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

The use of methotrexate in children with rheumatic diseases

R Gutiérrez-Suárez1, R Burgos-Vargas

  • 1Department of Rheumatology, Hospital General de México, México.

Clinical and Experimental Rheumatology
|November 4, 2010
PubMed

Insights

Methotrexate (MTX) is a safe and effective standard treatment for juvenile idiopathic arthritis (JIA) and other pediatric rheumatic diseases. It serves as a benchmark for comparing other disease-modifying anti-rheumatic drugs (DMARDs) and biologics in clinical trials.

Area of Science:

  • Pediatric Rheumatology
  • Pharmacology

Background:

  • Methotrexate (MTX) is a cornerstone therapy for pediatric rheumatic conditions like juvenile idiopathic arthritis (JIA).
  • It is particularly vital for JIA subgroups with a polyarticular course.
  • MTX efficacy and safety data in children are well-established.

Purpose of the Study:

  • To highlight the role of MTX in treating pediatric rheumatic diseases.
  • To emphasize MTX as the standard of care for JIA.
  • To underscore MTX's safety profile in pediatric patients.

Main Methods:

  • Review of existing clinical data and trial results.
  • Analysis of treatment outcomes and safety profiles.
  • Comparison of MTX with other disease-modifying anti-rheumatic drugs (DMARDs) and biologics.

Main Results:

  • MTX demonstrates significant efficacy and remission rates in JIA, establishing it as a benchmark in trials.
  • It is the preferred DMARD for JIA, used alone or with biologics.
  • Long-term data confirm MTX's safety in the pediatric population.

Conclusions:

  • Methotrexate is the drug of choice for JIA and other pediatric rheumatic diseases.
  • Its established efficacy and safety make it a vital therapeutic agent.
  • MTX serves as a critical comparator for novel treatments in pediatric rheumatology.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...